[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353165-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353165-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","insulin-resistance-as-a-systemic-metabolic-risk-state-for-cancer-mechanisms-biomarkers-and-prevention","Insulin Resistance as a Systemic Metabolic Risk State for Cancer - Mechanisms, Biomarkers, and Prevention","","Insulin resistance (IR) extends beyond type 2 diabetes to function as a broader systemic metabolic risk state relevant to carcinogenesis. Chronic hyperinsulinemia can trigger IGF-1-dependent signaling, activating PI3K/Akt/mTOR and MAPK pathways that promote proliferation and suppress apoptosis. IR also aligns with oxidative stress, chronic low-grade inflammation, and epigenetic changes, shaping a tumor-supportive microenvironment. Epidemiology links IR to higher cancer risk, while causality remains tumor-type dependent. The review integrates mechanisms, epidemiology, biomarkers, and prevention, emphasizing earlier risk identification with integrated biomarker panels, lifestyle modification, and GLP-1–based therapies, while noting uncertainty in long-term cancer outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/insulin-resistance-as-a-systemic-metabolic-risk-state-for-cancer-mechanisms-biomarkers-and-prevention/353165/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/insulin-resistance-as-a-systemic-metabolic-risk-state-for-cancer-mechanisms-biomarkers-and-prevention/353165.png","ImageObject",300,407,{"name":42,"@type":43},"Aldword","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does insulin resistance contribute to cancer development?","Question",{"text":63,"@type":64},"Chronic hyperinsulinemia can activate IGF-1-dependent pathways, including PI3K/Akt/mTOR and MAPK signaling, promoting proliferation and limiting apoptosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which biomarkers are suggested for earlier cancer risk identification related to IR?",{"text":68,"@type":64},"The review highlights integrated biomarker approaches including fasting glucose, HOMA-IR, triglyceride-to-HDL ratio, high-sensitivity C-reactive protein, and IGF-1.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is cancer risk assessment based only on BMI limited in the context of IR?",{"text":72,"@type":64},"Metabolic dysfunction may occur even with normal BMI, so BMI alone can miss individuals with IR-related risk.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353165,1791073579,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":109,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Review  \nInsulin Resistance as a Systemic Metabolic Risk State for Cancer: Mechanisms, Biomarkers, and Prevention  \nMarijana Matek Sari´c 1,†, Nataša Lisica Šiki´c 1,†, Tamara Sori´c 2, *, Ana Sari´c 3, Andrija Ivanišin 4, Ivona Brodi´c 4 and Mirta Mili´c 5  \nAcademic Editor: Jean-François Tanti  \nReceived: 15 May 2026  \nRevised: 9 June 2026  \nAccepted: 15 June 2026  \nPublished: 18 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Health Studies, University of Zadar, Splitska 1, 23000 Zadar, Croatia;  \n[marsaric@unizd.hr](marsaric@unizd.hr) (M.M.S.); [nlisicasi@unizd.hr](nlisicasi@unizd.hr) (N.L.Š .)  \n2 Psychiatric Hospital Ugljan, Otoˇckih dragovoljaca 42, 23275 Ugljan, Croatia  \n3 School of Medicine, Catholic University of Croatia, Ilica 242, 10000 Zagreb, Croatia; [asaric1@unicath.hr](asaric1@unicath.hr)  \n4 Independent Researcher, 10000 Zagreb, Croatia; [andrija.ivanisin@gmail.com](andrija.ivanisin@gmail.com) (A.I.); [ivona.nutricionist@gmail.com](ivona.nutricionist@gmail.com) (I.B.)  \n5 Division of Toxicology, Institute for Medical Research and Occupational Health, Ksaverska cesta 2,  \n10000 Zagreb, Croatia; [mmilic@imi.hr](mmilic@imi.hr)  \n* Correspondence: [tamara.novoselic@pbu.hr](tamara.novoselic@pbu.hr); Tel.: +385-91-56-56-166 † These authors contributed equally to this work.  \nAbstract  \nInsulin resistance (IR) is traditionally viewed within the context of type 2 diabetes. However, it increasingly appears to represent a broader systemic metabolic risk state with potential relevance for carcinogenesis. Chronic hyperinsulinemia can activate insulin-like growth factor-1-dependent pathways, including phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin and mitogen-activated protein kinase signaling, promoting cellular proliferation while limiting apoptosis. At the same time, IR is closely linked to oxidative stress, chronic low-grade inflammation, and epigenetic alterations, together shaping a tumor-promoting microenvironment. Epidemiological studies report consistent associations between IR and increased cancer risk, particularly for endometrial, liver, and colorectal cancers. Yet causality remains uncertain and likely varies by tumor type. Notably, metabolic dysfunction may also occur in individuals with normal body mass index (BMI), underscoring the limitations of BMI-based risk assessment. Unlike previous reviews that primarily focused on individual mechanisms or epidemiological associations, this review examines IR as a systemic metabolic risk state by integrating molecular, epidemiological, biomarker-based, and prevention-oriented perspectives. Particular emphasis is placedon strategies for earlier risk identification using integrated biomarker approaches, including fasting glucose, homeostatic model assessment of insulin resistance, triglyceride-tohigh-density lipoprotein ratio, high-sensitivity C-reactive protein, and insulin-like growth factor-1 . Emerging tools such as continuous glucose monitoring and hepatokine profiling may further refine risk detection. Sustained lifestyle modification—diet, physical activity, sleep, and stress regulation—remains central to prevention. Pharmacological therapies, including glucagon-like peptide-1 receptor agonists and dual incretin agents, offer additional metabolic benefits, although their long-term impact on cancer risk is still unclear. Therefore, IR is best understood not as an isolated risk factor, but as a systemic metabolic risk state that may influence cancer development, with implications for prevention and early risk stratification.  \nKeywords: insulin resistance; cancer risk; hyperinsulinemia; metabolic biomarkers; metabolic risk state; risk stratification; cancer prevention; GLP-1 receptor agonists; tirzepatide; continuous glucose monitoring  \n1. Introductio","cbCais3XGt5YWdNv","https://ap.wps.com/l/cbCais3XGt5YWdNv","pdf",1288251,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"How does insulin resistance contribute to cancer development?\",\"answer\":\"Chronic hyperinsulinemia can activate IGF-1-dependent pathways, including PI3K/Akt/mTOR and MAPK signaling, promoting proliferation and limiting apoptosis.\"},{\"question\":\"Which biomarkers are suggested for earlier cancer risk identification related to IR?\",\"answer\":\"The review highlights integrated biomarker approaches including fasting glucose, HOMA-IR, triglyceride-to-HDL ratio, high-sensitivity C-reactive protein, and IGF-1.\"},{\"question\":\"Why is cancer risk assessment based only on BMI limited in the context of IR?\",\"answer\":\"Metabolic dysfunction may occur even with normal BMI, so BMI alone can miss individuals with IR-related risk.\"}]","Insulin Resistance as a Systemic Metabolic Risk State for Cancer - Mechanisms, Biomarkers, and Prevention | PDF",1790103386,101,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38948ad4379850826801c940fd0b341a.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a93bc675fb9253e0c985e041c56b2bd.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c14c0470a9461a6880e2927c66e8e11a.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bdac2184cd839e389f89162d253428c4.webp",980,1385]